Presentation is loading. Please wait.

Presentation is loading. Please wait.

Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray  Eli O. Meltzer,

Similar presentations


Presentation on theme: "Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray  Eli O. Meltzer,"— Presentation transcript:

1 Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray  Eli O. Meltzer, MDa, b, Alfredo A. Jalowayski, PhDb, H.Alice Orgel, MD, PhDa, b, Alan G. Harris, MDc  Journal of Allergy and Clinical Immunology  Volume 102, Issue 1, Pages (July 1998) DOI: /S (98) Copyright © 1998 Mosby, Inc. Terms and Conditions

2 Fig. 1 Total SAR symptom/sign score (mean ± SEM). Sum of separate nasal and nonnasal scores, with clinician and patient assessments for morning and evening. *p < 0.05, mometasone furoate versus placebo. Journal of Allergy and Clinical Immunology  , 39-49DOI: ( /S (98) ) Copyright © 1998 Mosby, Inc. Terms and Conditions

3 Fig. 2 Nasal symptom/sign score (mean) for each symptom on each visit, with clinician and patient evening assessments. *p < 0.05; **p < 0.01, mometasone furoate versus placebo. B, Baseline. Journal of Allergy and Clinical Immunology  , 39-49DOI: ( /S (98) ) Copyright © 1998 Mosby, Inc. Terms and Conditions

4 Fig. 3 Clinician and patient assessment of therapeutic response. Percent of patients in mometasone furoate and placebo treatment groups with each rating of improvement on day 8 and day 15. *p < 0.05 mometasone furoate versus placebo. Journal of Allergy and Clinical Immunology  , 39-49DOI: ( /S (98) ) Copyright © 1998 Mosby, Inc. Terms and Conditions

5 Fig. 4 Percent of patients with increase or decrease in eosinophils, basophils, and neutrophils among those with evaluable paired pre- and posttreatment specimens. *p ≤ 0.05; **p ≤ 0.001, mometasone furoate versus placebo. p ≤ 0.05 baseline to day 15 within treatment. Journal of Allergy and Clinical Immunology  , 39-49DOI: ( /S (98) ) Copyright © 1998 Mosby, Inc. Terms and Conditions

6 Fig. 5 Concentration (mean ± SEM) of ECP, tryptase, histamine, and albumin in NL fluid at baseline and day 15. *p ≤ 0.05, **p ≤ within treatment, baseline to day 15. Journal of Allergy and Clinical Immunology  , 39-49DOI: ( /S (98) ) Copyright © 1998 Mosby, Inc. Terms and Conditions


Download ppt "Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray  Eli O. Meltzer,"

Similar presentations


Ads by Google